1. Sethi S，Nester CM，Smith RJ.Membranoproliferative glomerulonephritis and C3 glomerulopathy：resolving the confusion.Kidney Int，2012，81（5）：434-441.

2. Alchi B，Jayne D.Membranoproliferative glomerulonephritis.Pediatr Nephrol，2010，25（8）：1409-1418.

3. Sethi S，Fervenza FC.Membranoproliferative glomerulonephritis-A new look at an old entity.N Engl J Med，2012，366（12）：1119-1131.

4. Fakhouri F，Frémeaux-BacchiV，Noël LH，et al.C3 glomerulopathy：a new classification. Nat Rev Nephrol，2010，6 （8）：494-499.

5. Li LS，Liu ZH.Epidemiology data of renal disease from a single unit inChina：analysis based on 13519 renal biopsies.Kidney Int，2004，66：920-923.

6. Zhou FD，Zhao MH，Wan ZZ，et al.The changing spectrum of primary glomerular diseases within the last 15 years：A survey of 3331 patients in a single Chinese centre.Nephrol Dial Transplant，2009，24：870-876.

7. Zhou XJ，Silva FG.Membranoproliferative glomerulonephritis//Jennette JC，Olsen JL，Schwartz MM，et al. Heptinstall’s pathology of the kidney.6th ed.Philadelphis：Lippincott Williams＆Willkins，2007：253-319.

8. Cansick JC，Lennon R，Cummins CL，et al.Prognosis，treatment and outcome of children mesangiocapillary（membranoproliferative）glomerulonephritis.Nephrol Dial Transplant，2004，19：2769-2777.

9. Kamar N，Rostaing L，Alric L.Treatment of hepatitis C virus-related glomerulonephritis.Kidney Int，2006，69：436-439.

10.王素霞，邹万忠，王海燕.透射电镜检查在冷球蛋白血症肾损害诊断中的作用.中华肾脏病杂志，2005，21：328-332.

11. Dillon JJ，Hladunewich M，Haley WE，et al. Rituximab therapy for TypeⅠmembranoproliferative glomerulonephritis.Clin Nephrol，2012，77（4）：290-295.

12. Servais A，Frémeaux-Bacchi V，Lequintrec M，et al.Primary glomerulonephritis with isolated C3 deposits：a new entity which shares common genetic risk factors with hemolytic uremic syndrome. J Med Genet，2007，44：193-199.

13. Pickerina MC，D’Agati VD，Nester CM，et al.C3 glomerulopathy：consensus report. Kidney Int，2013，84：1079-1089.

14. Fang CJ，Frémeaux-Bacchi V，Liszewski MK，et al.Membrane cofactor protein mutations in atypical hemolytic uremic syndrome（aHUS），fatal Stx-HUS，C3 glomerulonephrits，and the HELLP syndrome. Blood，2008，111：624-632.

15. Habbig S，Mihatsch MJ，Heinen S，et al. C3 deposition glomerulopathy due to a functional factor H defect.Kidney Int，2009，75：1230-1234.

16. Dragon-Durey MA，Frémeaux-Bacchi V，Loirat C，et al. Heterozygous and homozagous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis report and genetic analysis of 16 cases.J Am Soc Nephrol，2004，15：787-795.

17. Heurich M，Martinez-Barricarte R，Francis NJ，et al.Common polymorphism in C3，factor B，and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA，2011，108：8761-8766.

18. Sethi S，Fervenza FC，Zhang YZ，et al.C3 glomerulonephritis：clinicaopathological findings，complement abnormalities，glomerular proteomic profile，treatment，and follow-up.Kidney Int，2012，82：465-473.

19. Servais A，Noël LH，Roumenina LT，et al.Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.Kidney Int，2012，82（4）：454-464.

20. Martinez-Barricarte R，Heurich M，Valdes-Cañedo F，et al.Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest，2010，120：3702-3712.

21. Gale DP，deJorge EG，Cook HT，et al.Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet，2010，376：794-801.

22. Heurich M，Martinez-Barricarte R，Francis NJ，et al.Common polymorphism in C3，factor B，and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA，2011，108：8761-8766.

23. Pickering MC，Cook HT，Warren J，et al.Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.Nat Genet，2002，31：424-428.

24. Rose KL，Paixao-Cavalcante D，Fish J，et al.Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.J Clin Invest，2008，118 2：608-618.

25. Fakhouri F，Goicochea de Jorge E，Brune F，et al.Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int，2012，78：279-286.

26. Sethi S，Fervenza FC，Zhang YZ，et al.C3 glomerulonephritis：clinicaopathological findings，complement abnormalities，glomerular proteomic profile，treatment，and follow-up.Kidney Int，2012，82：465-473.

27. Sethi S，Sukov WR，Zhang Y，et al.Dense deposit disease associated with monoclonal gammopathy of undetermined significance.Am J Kidney Dis，2012，56：977-982.

28. Nasr SH，Valeri AM，Appel GB，et al.Dense deposit disease：clinicopathologic study of 32 pediatric and adult patients.Clin J Am Soc Nephrol，2009，4（1）：22-32.

29.喻小娟，刘刚，赵明辉.12例C3肾小球肾炎的临床病理特点及其血浆补体活化成分分析.中华肾脏病杂志，2011，27：797-801.

30. Smith RJH，Alexander J，Barlow PN，et al.New approaches to the treatment of dense deposit disease.J Am Soc Nephrol，2007，18：2447-2456.